Reuters logo
BRIEF-Aerie Pharma's Roclatan succeeds in second late-stage study
May 24, 2017 / 8:08 PM / 4 months ago

BRIEF-Aerie Pharma's Roclatan succeeds in second late-stage study

May 24 (Reuters) - Aerie Pharmaceuticals Inc

* Aerie pharmaceuticals reports positive roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results

* Aerie pharmaceuticals inc - ‍roclatan™ successfully achieves primary efficacy endpoint in mercury 2 study​

* Aerie pharmaceuticals inc - ‍if mercury 1 12-month safety results are also successful, we expect to submit roclatan nda in first half of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below